Jefferies raises Livanova stock price target to $120 on guidance
Jefferies increased its price target for LivaNova (NASDAQ:LIVN) to $120 from $100, maintaining a Buy rating. The company reported Q3 sales of $393M, up 10%, and EPS of $1.23, up 20%, both beating estimates. LivaNova raised its full-year sales growth guidance to 9-10% and EPS guidance to $4.40-$4.50. The stock has a market cap of $5.33B and a PEG ratio of 0.12, according to InvestingPro.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to attract buying interest, especially from investors focused on growth medical device stocks.
Market read
The new guidance and earnings beat provide fresh material for traders to consider positioning in LIVN.
What to watch
Potential regulatory or reimbursement risks in key markets could temper the positive outlook.
Background
LIVN reported Q3 sales of $393 million, up 10% YoY, and EPS of $1.23, beating estimates, prompting a guidance lift.
Ticker impact
Jefferies raised LIVN price target to $120 and upgraded guidance after the company's Q3 earnings beat and full-year outlook increase.
likely upward pressure as investors price in higher earnings guidance
The new guidance of $4.40‑$4.50 per share and higher sales outlook indicate stronger future performance, prompting buying interest.
Market effects
Medical device sector may see broader uplift as LIVN's strong results highlight demand for cardiopulmonary and neuromodulation products.
European and Asian markets could react to LIVN's guidance as investors assess global demand for its devices.
Limited to LIVN and peers; not a macro driver.
Counterpoint
If the market has already priced in the earnings beat, the guidance raise may be already reflected, limiting upside.
Key entities
- CompanyLivaNova PLC
Medical device manufacturer reporting Q3 results.
- AnalystJefferies
Raised price target and maintained Buy rating.
